Solid tumor
BioNTech’s CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
Relay postpones its rare cancer drug approval plans due to IRA, losing ground to competitors
Relay Therapeutics is altering its strategic course, driven by the effects of the Inflation Reduction Act (IRA), leading the biotech ...
Sotio halts trials of IL-15 drug in solid tumors due to lack of efficacy, casting doubt on cytokine’s potential
Sotio Biotech has decided to halt ongoing studies of its IL-15 superagonist, nanrilkefusp alfa, due to insufficient efficacy in clinical ...
Exscientia Shifts Focus: Consolidates ‘Rapidly Emerging Pipeline’ to Emphasize 2 Key Oncology Programs
Exscientia, an AI-driven precision medicine company, is streamlining its pipeline to concentrate on the highest-value opportunities. The company is focusing ...
ALX Oncology’s CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials
ALX Oncology is reevaluating the potential of its anti-CD47 drug in the context of solid tumors, buoyed by promising data. ...
Moderna expands cancer vaccine portfolio with Immatics deal worth up to $1.7B
Moderna is intensifying its focus on cancer vaccines and cell therapies through a newly announced research partnership with Immatics, a ...
FDA Approves IND for Selected Advanced Solid Tumors Using ADRX-0706
Source – Adcentrx Therapeutics The FDA has granted clearance to Adventrx Therapeutics’ IND application for ADRX-0706, a promising treatment for ...
